Based on a desktop review of Virtus, Genea and Monash. Monash is the lesser of the two listed IVF businesses and behind Genea in terms of premium pricing power. Monash seems worth a punt at the right price, but VRT is a more stable group and hasn't suffered the issues of major doctor departures. So for what it's worth, I have played Monash as an in and out, rather than a buy and hold. It says something that the banks required almost all the new equity raised be allocated to debt repayment - ie the banks aren't confident.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
80.5¢ |
Change
0.005(0.63%) |
Mkt cap ! $313.6M | |||
| Open | High | Low | Value | Volume |
| 80.0¢ | 82.0¢ | 80.0¢ | $2.201M | 2.719M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1913 | 80.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 82.0¢ | 69071 | 3 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| MVF (ASX) Chart |